Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model
- PMID: 1501110
Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model
Abstract
The influence of the time of dexamethasone (DEX) administration (0.5 mg i.v.) on the suppression of plasma hydrocortisone (HC) was investigated in six healthy subjects, by comparing dosage times of 8 and 20 hr. To estimate HC production after DEX administration a pharmacokinetic model was developed and applied to the time course of plasma HC. This model was based on the assumption that HC production could be described as a continuous i.v. infusion, that stops and starts instantaneously. After DEX at 8 hr, HC production was reduced instantaneously to a minimum level and HC disappeared rapidly from plasma with an elimination half-life of 1.32 +/- 0.28 hr (mean +/- S.D.). Almost complete suppression of HC production lasted for 20 hr. The nocturnal increase in HC production at 20 hr after DEX administration was still attenuated compared to the preceding night. After DEX administration at 20 hr, plasma HC was lower than control for about 20 hr, but it was not reduced to the very low level observed after DEX dosage in the morning. Approximately 20 hr after dosage of DEX at 20 hr, HC production seemed to follow the normal diurnal variation of the control values again. To explain the difference in HC suppression by DEX at different dosage times, we constructed a curve describing the relationship between DEX concentration and suppression of the sudden increase in HC production during the night. This curve indicates that HC suppression by DEX could be completely dependent on DEX concentration, without a DEX independent circadian variation.
Similar articles
-
Kinetic-dynamic modeling of lymphocytopenia induced by the combined action of dexamethasone and hydrocortisone in humans, after inhalation and intravenous administration of dexamethasone.J Pharmacol Exp Ther. 1992 Aug;262(2):509-15. J Pharmacol Exp Ther. 1992. PMID: 1501111
-
Sensitivity of the hypothalamic-pituitary-adrenal system of pigeons (Columba livia domestica) to suppression by dexamethasone, cortisol, and prednisolone.Avian Dis. 1994 Jul-Sep;38(3):435-45. Avian Dis. 1994. PMID: 7832695
-
Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone.Cell Immunol. 1993 Jun;149(1):39-49. doi: 10.1006/cimm.1993.1134. Cell Immunol. 1993. PMID: 8513511
-
Influence of morning or evening administration on absorption of theophylline.Zhonghua Yi Xue Za Zhi (Taipei). 2000 Feb;63(2):113-8. Zhonghua Yi Xue Za Zhi (Taipei). 2000. PMID: 10677921 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma.J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):355-72. doi: 10.1007/s10928-007-9050-8. Epub 2007 Feb 23. J Pharmacokinet Pharmacodyn. 2007. PMID: 17318442
-
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.AAPS PharmSci. 2000;2(3):E22. doi: 10.1208/ps020322. AAPS PharmSci. 2000. PMID: 11741238 Free PMC article.
-
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy.Oncologist. 2021 Apr;26(4):269-273. doi: 10.1002/onco.13680. Epub 2021 Feb 26. Oncologist. 2021. PMID: 33465258 Free PMC article. Review.
-
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.J Pharmacokinet Biopharm. 1999 Apr;27(2):127-47. doi: 10.1023/a:1020670421957. J Pharmacokinet Biopharm. 1999. PMID: 10567952
-
Dexamethasone facilitates fear extinction and safety discrimination in PTSD: A placebo-controlled, double-blind study.Psychoneuroendocrinology. 2017 Sep;83:65-71. doi: 10.1016/j.psyneuen.2017.05.023. Epub 2017 May 31. Psychoneuroendocrinology. 2017. PMID: 28595089 Free PMC article.